CARACTERIZAÇÃO E AVALIAÇÃO DO POTENCIAL ANTITUMORAL IN VITRO DE CÉLULAS NK-92-CAR ANTI-GD2 COM EXPRESSÃO DE GITRL
O desenvolvimento de terapias alogênicas (off-the-shelf) utilizando o Receptor Quimérico de Antígeno (CAR) visa reduzir limitações das terapias autólogas, como a necessidade de compatibilidade HLA e aumento do tempo de espera do paciente em razão do tempo de manufatura. Nesse contexto, as células NK...
Main Authors: | MC Tirapelle, D Tadeu, VP Castro |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2023-10-01
|
Series: | Hematology, Transfusion and Cell Therapy |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2531137923011616 |
Similar Items
-
CD19 CAR-NK CONSTRUCTION WITH A NEW HINGE AND GITRL CO-EXPRESSION FOR TREG ACTIVITY INHIBITION
by: DF Schmidt, et al.
Published: (2023-10-01) -
EMPOWERING CAR-T CELL THERAPY: GITRL COSTIMULATION FOR ENHANCED ANTITUMOR RESPONSE AND IMMUNOSSUPPRESSION RESISTANCE IN SOLID TUMORS
by: IP Furtado, et al.
Published: (2023-10-01) -
Anti-tumor efficacy of anti-GD2 CAR NK-92 cells in diffuse intrinsic pontine gliomas
by: Pengcheng Zuo, et al.
Published: (2023-05-01) -
Target-Dependent Expression of IL12 by synNotch Receptor-Engineered NK92 Cells Increases the Antitumor Activities of CAR-T Cells
by: Hong Luo, et al.
Published: (2019-12-01) -
The TNF receptor-ligands 4-1BB-4-1BBL and GITR-GITRL in NK cell responses
by: Isabel eBarao
Published: (2013-01-01)